Company intelligence / Profile preview

Istituto Gentili

Ownership: Private
Development stage: Commercial

Overview

Istituto Gentili S.r.l. is an Italian biopharmaceutical company with over a century of history. Now part of the Mediolanum Farmaceutici group, it focuses exclusively on oncology and oncohematology since its relaunch in the late 2010s. The company offers a portfolio of innovative therapeutic solutions for advanced breast cancer, non-Hodgkin’s lymphoma, pain management, febrile neutropenia, and oropharyngeal mucositis. Its products are commercialized primarily in Italy with growing turnover reflecting clinical value.[1][2]

Therapeutic areas: OncologyHematology
Modalities: small molecules (e.g., aromatase inhibitors, fentanyl)supportive care agents[3]possibly biologics for oncohematology (not explicitly stated)
Industry: Biotech

Partnerships

Collaborates with leading market players and scientific community; specifics undisclosed but emphasizes partnerships as strategic pillar.[3]

Beyond the preview

Go deeper on Istituto Gentili.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Istituto Gentili.

Explore the full profile